false
0002032966
0002032966
2025-07-31
2025-07-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported)
July 31, 2025
Acuren Corporation
(Exact Name of Registrant as Specified in its
Charter)
| Delaware |
|
001-42524 |
|
66-1076867 |
|
(State or Other Jurisdiction
of
Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
14434 Medical Complex Drive,
Suite 100
Tomball, TX |
|
77377 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (800) 218-7450
(Former name or former address, if changed since
last report) Not Applicable
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
TIC |
|
The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
| ☒ |
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On July 31, 2025, Acuren Corporation (the “Company”)
held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders voted on the (i) approval
of the issuance of shares of common stock, par value $0.0001 per share of the Company (the “Common Stock”), to stockholders
of NV5 Global, Inc. (“NV5”) in connection with the Agreement and Plan of Merger dated May 14, 2025, by and among the Company,
NV5, and certain direct, wholly owned subsidiaries of the Company (Proposal 1), (ii) election of eight director nominees (Proposal 2),
(iii) ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered accounting firm for
the 2025 fiscal year (Proposal 3), and (iv) approval of the Company’s 2025 Employee Stock Purchase Plan (Proposal 4). The proposal
to approve the adjournment of the Annual Meeting was not voted on at the Special Meeting because there were sufficient votes
to approve Proposal 1.
The results of the votes are set forth below.
Proposal 1—Approval of the Issuance of Shares of the Company
to Stockholders of NV5
The stockholders approved the issuance of shares
of Common Stock to stockholders of NV5 in connection with the Agreement and Plan of Merger.
| For | | |
Against | | |
Abstain | |
| | 94,157,704 | | |
| 6,285 | | |
| 24,153 | |
Proposal 2—Election of Directors
The stockholders voted in favor of the election
of the following director nominees as directors for a term of office expiring at the Company’s 2026 Annual Meeting of Stockholders
and, in each case, until his or her successor is duly elected and qualified.
| | |
For | | |
Against | | |
Abstain | |
| Sir Martin E. Franklin | |
| 91,027,329 | | |
| 3,149,584 | | |
| 11,229 | |
| Robert A. E. Franklin | |
| 93,192,053 | | |
| 983,560 | | |
| 12,529 | |
| Antoinette C. Bush | |
| 94,074,314 | | |
| 78,105 | | |
| 35,723 | |
| Rory Cullinan | |
| 94,148,401 | | |
| 28,418 | | |
| 11,323 | |
| Elizabeth Meloy Hepding | |
| 94,094,716 | | |
| 57,668 | | |
| 35,758 | |
| Peter Hochfelder | |
| 94,138,229 | | |
| 38,290 | | |
| 11,623 | |
| James E. Lillie | |
| 90,173,481 | | |
| 4,003,337 | | |
| 11,324 | |
| Talman Pizzey | |
| 94,087,506 | | |
| 89,313 | | |
| 11,323 | |
Proposal 3—Ratification of Appointment of Independent Registered
Public Accounting Firm
The stockholders approved the ratification of the
appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending
December 31, 2025.
| For | | |
Against | | |
Abstain | |
| | 94,155,216 | | |
| 21,803 | | |
| 11,123 | |
Proposal 4—Approval of the Company’s 2025 Employee
Stock Purchase Plan
The stockholders approved the 2025 Employee Stock
Purchase Plan.
| For | | |
Against | | |
Abstain | |
| | 94,139,694 | | |
| 34,925 | | |
| 13,523 | |
Item
7.01 Regulation FD
Acuren issued a press
release on July 31, 2025, announcing the voting results of the Annual Meeting, which is furnished hereto as Exhibit 99.1 and incorporated
into this Item 7.01 by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| |
|
|
| 99.1 |
|
Press Release, dated July 31, 2025. |
| |
|
|
| 104 |
|
Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Acuren Corporation |
| |
|
|
| |
By: |
/s/ Kristin Schultes |
| |
Name: |
Kristin Schultes |
| |
Title: |
Chief Financial Officer |
Date: July 31, 2025
